La Vanguardia published a press release: 'The future of biotechnology: lower-cost treatments in a short period of time'

by Som Biotech

4 years ago
Central Nervous System, La Vanguardia, biotechnology, Artificial Intelligence, rare diseases

SOM Biotech has designed a computational Artificial Intelligence-based method to analyze molecular structures and select the best option after performing more than 2.5 million comparisons in each p...

La Marató awards funding to a rare diseases project at IRB Barcelona

by IRB Barcelona - Instituto de Investigación Biomédica

4 years ago
rare diseases, Marató, TV3, Cohen Syndrome

The collaborative project will focus on identifying the cellular defects that lead to Cohen Syndrome. Awarded €400,000 of funding, the project will last for 3 years. The Microtubule Organizati...

SOM Biotech continues working during coronavirus outbreak to bring therapies for patients with rare diseases

by Som Biotech

5 years ago
SOMAI PRO technology, rare diseases, therapies

While the coronavirus outbreak grows worldwide, at SOM Biotech we continue working on our pipeline to bring therapies for patients with rare diseases.

Sant Joan de Déu Research Foundation of Barcelona leads this European project that aims to connect and empower families living with rare diseases, and collect data to advance research

by Hospital Sant Joan de Déu

6 years ago
social network, european, rare diseases, Share4Rare

Share4Rare is born, the first social media network to connect patients, caregivers and researchers of rare diseases around the globe

Minoryx Therapeutics appoints Didier Le Normand as Group Chief Financial Officer (CFO) and General Manager of its Belgian subsidiary

by Minoryx Therapeutics

6 years ago
Minoryx Therapeutics, appointment, rare diseases

Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, today announces that it has appointed Didier Le Normand as Group CFO as well as General Manager of its...

The Barcelona Macula Foundation participates in World Rare Disease Day and continues researching into Stargardt’s disease and Retinitis Pigmentosa

by BMF Barcelona Macula Foundation: Research for Vision

6 years ago
BMF, Rare diseases, Stargardt's disease, Retinitis Pigmentosa

For another year, the Barcelona Macula Foundation (BMF) is participating in World Rare Disease Day, whose main aim is to sensitise, educate and inform the public about these pathologies and positio...

SOM Biotech announces a worldwide license with Corino Therapeutics for its SOM0226 compound against amyloidosis

by Som Biotech

8 years ago
SOM Biotech, rare diseases, license agreement, U.S. Corino Therapeutics, Transthyretin Amyloidosis

SOM Biotech, a leading clinical-stage biopharmaceutical company specialized in drug repurposing to treat rare diseases with a focus on CNS diseases today announces an exclusive worldwide license agree...

Researchers find a gene that causes Opitz C syndrome in the only patient with this rare disorder in Catalonia

by Universitat de Barcelona

8 years ago
p.Q638*, gene MAGEL2, Opitz C syndrome, rare diseases, chromosome 15, Prader-Willi Region

In the new study, the experts described for the first time, the existence of a novo mutation –p.Q638*- located in the gene MAGEL2 of the only diagnosed person with Opitz C syndrome in Catalonia. Ide...

Ramón Areces Foundation, new UB researchers on rare diseases, tumor progression and cellular stress

by Universitat de Barcelona

8 years ago
Ramón Areces Foundation, rare diseases

Research projects led by UB researchers Francesc Palau Martínez, Marçal Pastor-Anglada and Antonio Zorzano Olarte will receive financial support from the Ramón Areces Foundation, in the eighteenth ...

New drug discovery company in the area of rare diseases

by CIC bioGUNE

8 years ago
Atlas Molecular Pharma, rare diseases, CRB Inverbío, Kereon Partners

The new company, Atlas Molecular Pharma, aims to develop a technology capable of detecting molecules which stabilize proteins involved in the development of certain rare diseases. The venture capital ...